TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25041740

Group type: EXPERIMENTAL
Intervention: LL-37 (0.5 mg/mL)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: LL-37 (1.6 mg/mL)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: LL-37 (3.2 mg/mL)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 21933833

Group type: EXPERIMENTAL
Intervention: Valsartan (20 mg daily) for 30 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20698232

Group type: EXPERIMENTAL
Intervention: Perioperative oral nutrition with branched chain amino acids (BCAA) - 11 patients, received BCAA supplement twice daily plus a usual diet for 14 days before operation and on days 1 to 7 after operation.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual diet - 13 patients, received a usual diet alone.
Number of subjects: 24
Study: 18166545

Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Number of subjects: 330

Group type: COMPARATOR
Intervention: Rectal diazepam
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Buccal midazolam (for children without malaria)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Rectal diazepam (for children without malaria)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Buccal midazolam and Rectal diazepam
Number of subjects: 330
Study: 15639168

Group type: EXPERIMENTAL
Intervention: PROP bitterness
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sweetness of scotch
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Greater sweetness and less bitterness from sampled scotch
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Preference ratings for beer
Number of subjects: 49
Study: 14516884

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibrinolytic therapy
Number of subjects: 0
Study: 10502866

Group type: EXPERIMENTAL
Intervention: Internet-based questionnaires (WWW) with anonymity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Internet-based questionnaires (WWW) without anonymity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper-based questionnaires with nonanonymity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paper-based questionnaires with anonymity
Number of subjects: 0
Study: 8743403

Group type: EXPERIMENTAL
Intervention: Cefadroxil 250 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cefadroxil 500 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cefadroxil 1000 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cephalexin 250 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cephalexin 500 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cephalexin 1000 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cefadroxil
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both cefadroxil and cephalexin
Number of subjects: 36
Study: 1672589

Group type: EXPERIMENTAL
Intervention: Family psychoeducation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social skills training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of family psychoeducation and social skills training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social skills training alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Family condition or combined family/social skills condition
Number of subjects: 0
Study: 7293945

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31072599

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (ImRs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Writing Rescripting (WRs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recall only (ImRE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No recall + no manipulation (NM)
Number of subjects: 0
Study: 31030986

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) programme
Number of subjects: 8482

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 8482
Study: 28874242

Group type: EXPERIMENTAL
Intervention: micro-dose rhEpo (20 IU/kg/week)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: low-dose rhEpo (60 IU/kg/week)
Number of subjects: 25

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 25
Study: 26813915

Group type: EXPERIMENTAL
Intervention: TEVAR (thoracic endovascular aortic repair)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Risk score calculation for all-cause mortality
Number of subjects: 625
Study: 23986461

Group type: EXPERIMENTAL
Intervention: Combined methylphenidate therapy and EEG feedback training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methylphenidate therapy and non‐feedback attention training (Control)
Number of subjects: 40
Study: 21733603

Group type: EXPERIMENTAL
Intervention: 0.18 g/kg/day citrulline for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (iso-nitrogenous)
Number of subjects: 12
Study: 18486778

Group type: EXPERIMENTAL
Intervention: Intraoral vertical ramus osteotomy (IVRO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sagittal split ramus osteotomy (SSRO)
Number of subjects: 30
Study: 17178941

Group type: EXPERIMENTAL
Intervention: Meniett device therapy
Number of subjects: 61
Study: 12658071

Group type: EXPERIMENTAL
Intervention: Ecopipam (0, 30 or 100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg/70 kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg/70 kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ecopipam and Triazolam (compared to placebo)
Number of subjects: 10
Study: 11091263

Group type: EXPERIMENTAL
Intervention: Parents' method (biweekly phone calls to record calendar information)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Educators' method (monthly calendar returns)
Number of subjects: 333
Study: 8628162

Group type: EXPERIMENTAL
Intervention: MAC (bupivacaine, adrenaline, and cocaine)
Number of subjects: 181

Group type: COMPARATOR
Intervention: TAC (tetracaine, adrenaline, and cocaine)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: MAC
Number of subjects: 181

Group type: COMPARATOR
Intervention: TAC
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: MAC and TAC
Number of subjects: 181
Study: 1451342

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) administered subcutaneously once weekly, dosage titrated to maintain hematocrit at 35-38%.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (self-comparison)
Number of subjects: 7
Study: 6391074

Group type: EXPERIMENTAL
Intervention: 0.2 g zinc sulphate 3 times daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30100295

Group type: EXPERIMENTAL
Intervention: Cranial technique of the 4th ventricle compression (CV4)
Number of subjects: 30
Study: 28951403

Group type: EXPERIMENTAL
Intervention: Prevention programme
Number of subjects: 9121

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 9121
Study: 24809305

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for eight weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 20
Study: 22986112

Group type: EXPERIMENTAL
Intervention: Topical prostaglandin analog (latanoprost 0.005%)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study: 21620591

Group type: EXPERIMENTAL
Intervention: Behavioral treatments for cannabis use disorders
Number of subjects: 586
Study: 19220066

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine extended-release (CER) 30 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cyclobenzaprine immediate-release (CIR) 10 mg administered every 8 hours for a total of three doses
Number of subjects: 18
Study: 16826087

Group type: EXPERIMENTAL
Intervention: Patients with true CRS (559 patients)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Patients classified as normal (144 patients)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Patients with true CRS (460 patients)
Number of subjects: 703
Study: 14763665

Group type: EXPERIMENTAL
Intervention: Self-pressure (SP) group - antihypertensive therapy based on home blood pressure measurements.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Office pressure (OP) group - antihypertensive therapy based on blood pressure measured in the outpatient clinic.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Cost-minimization analysis of the SP strategy compared to standard practice (OP group).
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Medication compliance recorded in random subgroups of SP and OP groups using MEMS V TrackCaps.
Number of subjects: 360
Study: 10866006

Group type: EXPERIMENTAL
Intervention: Atropine 1.0 mg intravenously after 5 min of steady state
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium chloride administered after 10 min (group B)
Number of subjects: 20
Study: 9200357

Group type: EXPERIMENTAL
Intervention: Infasurf (n = 303, treatment arm)
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Infasurf (n = 180, prevention arm)
Number of subjects: 982

Group type: COMPARATOR
Intervention: Infasurf and Survanta (both arms)
Number of subjects: 982
Study: 1412608

Group type: EXPERIMENTAL
Intervention: Cefepime 2 g IVPB q 12 h
Number of subjects: 33

Group type: COMPARATOR
Intervention: Gentamicin 1.5 mg/kg IVPB q 8 h plus mezlocillin 4 g IVPB q 6 h
Number of subjects: 33
Study: 3929314

Group type: EXPERIMENTAL
Intervention: Deprenyl 10 mg/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Deprenyl 30 mg/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Deprenyl 60 mg/day
Number of subjects: 11

Group type: COMPARATOR
Intervention: Tranylcypromine
Number of subjects: 11
Study: 29534483

Group type: EXPERIMENTAL
Intervention: Optimal deployment condition based on height and tilt angle; noise-filtering scheme for RF signals.
Number of subjects: 0
Study: 27737676

Group type: EXPERIMENTAL
Intervention: 100 Mile Club® (walking/running program)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Just Move™ (classroom-based PA program)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Both interventions (100 Mile Club® and Just Move™)
Number of subjects: 1200
Study: 24827514

Group type: EXPERIMENTAL
Intervention: Group A (pedicle screw insertion position A)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Group B (pedicle screw insertion position B)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Group A
Number of subjects: 210

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 210
Study: 22079177

Group type: EXPERIMENTAL
Intervention: α-lactalbumin-enriched and symbiotic-supplemented infant formula
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 97
Study: 19608168

Group type: EXPERIMENTAL
Intervention: Endometrin vaginal insert (two times a day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Endometrin vaginal insert (three times a day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vaginal gel (daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Endometrin treatments (two times and three times a day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Endometrin vaginal inserts
Number of subjects: 18
Study: 18361737

Group type: EXPERIMENTAL
Intervention: Normal-calorie CBJ (280 Cal/480 mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal-calorie control beverage (HFCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-calorie CBJ (38 Cal/480 mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water (480 mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nothing (no water/beverage)
Number of subjects: 0
Study: 17214336

Group type: EXPERIMENTAL
Intervention: Higher serum thymidine kinase 1 (S‐TK1) concentration
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lower serum thymidine kinase 1 (S‐TK1) concentration
Number of subjects: 120
Study: 14623542

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily and celecoxib 400 mg twice daily (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Exemestane 25 mg daily (group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg daily (group C)
Number of subjects: 20
Study: 10768619

Group type: EXPERIMENTAL
Intervention: [18F] fluorodopa uptake in patients with PD
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: [18F] fluorodopa uptake in the caudate nucleus
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: [18F] fluorodopa uptake in the frontal cortex
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Severity of motor symptoms of PD
Number of subjects: 28
Study: 8836901

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 10 mg.kg‐1.day‐1 and prednisolone 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid 10 mg.kg‐1.day‐1 and placebo
Number of subjects: 30
Study: 1478292

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and recombinant interleukin-2 (IL-2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 6491914

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 1 mg bumetanide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 1 mg bumetanide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral solution administration of 1 mg bumetanide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tablet administration of 1 mg bumetanide
Number of subjects: 12

Group type: COMPARATOR
Intervention: All administration routes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intramuscular and oral preparations
Number of subjects: 12
Study: 31368661

Group type: EXPERIMENTAL
Intervention: High dairy diet (HD) - 4 servings or more per day for 6 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Adequate dairy diet (AD) - 2 servings or less per day for 6 weeks
Number of subjects: 26
Study: 28856967

Group type: EXPERIMENTAL
Intervention: HemoSep Novel Collection Bag (N=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: C.A.T.S Plus Autotransfusion System (N=40)
Number of subjects: 80
Study: 26580489

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg once daily
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 25293818

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg BW (standard dose or SD group)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 0.05 mmol/kg BW (half dose or HD group)
Number of subjects: 17
Study: 22390457

Group type: COMPARATOR
Intervention: Text message reminders for MCV4 and Tdap immunizations
Number of subjects: 195

Group type: COMPARATOR
Intervention: Text message and paper-mailed reminders for Hib immunization recall
Number of subjects: 195
Study: 22945779

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 mcg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 mcg)
Number of subjects: 82
Study: 17611821

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (100 mg per day) along with ferrous sulphate (200 mg per day) and folic acid (5 mg per day) for 3 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with ferrous sulphate (200 mg per day) and folic acid (5 mg per day) for 3 months
Number of subjects: 100
Study: 16211731

Group type: EXPERIMENTAL
Intervention: Narcotrend monitoring (Group NI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional clinical practice (Group C)
Number of subjects: 30
Study: 11838797

Group type: EXPERIMENTAL
Intervention: Titanium miniplate fixation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stainless steel wire fixation
Number of subjects: 40
Study: 10429902

Group type: EXPERIMENTAL
Intervention: Remote interactive fiber‐optic NPL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemedicine applications in otolaryngology
Number of subjects: 0
Study: 7478837

Group type: EXPERIMENTAL
Intervention: Individualized developmental care
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 36
Study: 2147234

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 112

Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 112
Study: 6108751

Group type: EXPERIMENTAL
Intervention: gamma-acetylenic GABA (GAG)
Number of subjects: 10
Study: 28549180

Group type: EXPERIMENTAL
Intervention: Self-perception of aging (SPA)
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 1216
Study: 28568169

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 0.05 mg/kg IM q24h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (FLUT) 3,000 μg q12h
Number of subjects: 8
Study: 26382998

Group type: EXPERIMENTAL
Intervention: Standard oximeters (oxygen given if SpO2 <94%)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Modified oximeters (oxygen given if SpO2 <90%)
Number of subjects: 615
Study: 24108521

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 19

Group type: COMPARATOR
Intervention: abobotulinumtoxinA
Number of subjects: 19
Study: 20824706

Group type: EXPERIMENTAL
Intervention: HPV triaging policy
Number of subjects: 3319

Group type: COMPARATOR
Intervention: Colposcopy policy
Number of subjects: 3319
Study: 19389262

Group type: EXPERIMENTAL
Intervention: Acupuncture and placebo medicine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sham acupuncture and Flunarizine (10 mg once per night for the first 2 weeks, then 5 mg once per night for the next 2 weeks)
Number of subjects: 140
Study: 18181333

Group type: EXPERIMENTAL
Intervention: HIV vaccine trial with education and risk reduction counseling every six months
Number of subjects: 2546
Study: 15127144

Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 11808370

Group type: EXPERIMENTAL
Intervention: Saline application for 5 s
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Saline application for 10 s
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Saline application for 30 s
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Saline application for 1 min
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Saline application for 2 min
Number of subjects: 72

Group type: COMPARATOR
Intervention: Citric acid application for 3 min
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Burnishing with saline for 5 s
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Burnishing with saline for 10 s
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Burnishing with saline for 1 min
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Burnishing with saline for 2 min
Number of subjects: 72
Study: 9674806

Group type: EXPERIMENTAL
Intervention: Nimodipine 60 mg p.o., five times daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg p.o., three times daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 7985514

Group type: EXPERIMENTAL
Intervention: Antipyrine in Tibetan
Number of subjects: 33

Group type: COMPARATOR
Intervention: Antipyrine in Han
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Acetaminophen in Tibetan
Number of subjects: 33

Group type: COMPARATOR
Intervention: Acetaminophen in Han
Number of subjects: 33
Study: 2692576

Group type: EXPERIMENTAL
Intervention: Oral immunostimulant
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 810765

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium on study day 2 after placebo on study day 1
Number of subjects: 20
Study: 31415908

Group type: COMPARATOR
Intervention: GLP-1 RA exenatide (acute administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GLP-1 RA liraglutide (titrated up to 1.8 mg daily for 12 weeks)
Number of subjects: 0
Study: 26354385

Group type: EXPERIMENTAL
Intervention: Long-term domiciliary oxygen therapy (LTDOT) for more than 15 hours every day with continuous low flow (1-2 L/min) for 3 years
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no additional oxygen therapy)
Number of subjects: 54
Study: 26051926

Group type: COMPARATOR
Intervention: US patients
Number of subjects: 0
Study: 23333143

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day for 9 days
Number of subjects: 160
Study: 21529841

Group type: EXPERIMENTAL
Intervention: NFKB1 (g.-24519delATTG) variant
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: NFKBIA (g.-1004A>G) variant
Number of subjects: 271
Study: 19933718

Group type: EXPERIMENTAL
Intervention: Call method (investigator-initiated direct contact 'opt-out')
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Click method (provider-initiated electronic 'opt-in' referral)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Letter method (provider-mediated 'opt-in' referral letter)
Number of subjects: 1000
Study: 17132302

Group type: EXPERIMENTAL
Intervention: Alum/ALM + BCG
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo (vaccine diluent)
Number of subjects: 544
Study: 15492459

Group type: EXPERIMENTAL
Intervention: Occupational exposure to rayon manufacturing chemicals (RMC, containing predominantly carbon disulfide (CS(2)) and minor sulfuric acid)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy unexposed controls (Chinese)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Thai workers
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chinese workers
Number of subjects: 16
Study: 11769967

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 9010794

Group type: EXPERIMENTAL
Intervention: Preterm infants (33 total, including small-for-gestational age and appropriate-for-gestational age)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fullterm infants (19 total)
Number of subjects: 52